Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Interleukin-12/23 inhibitors
5 evidence topics · 4 sources
Recommendations for ustekinumab: ACG 2025 guideline
UNIFI pivotal trial efficacy of ustekinumab: ACG 2025 guideline
Comparative efficacy of ustekinumab after prior advanced therapy: AGA 2024 living guideline
“Ustekinumab demonstrated a likely important benefit over adalimumab, vedolizumab, ozanimod, etrasimod, and mirikizumab with a moderate certainty of evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biosimilars of infliximab, adalimumab, and ustekinumab can be considered equivalent to their originator drug in their efficacy in terms of therapy selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote